Alterity Therapeutics Announced Cash balance On September 30, 2023 Of A$16.7M
Portfolio Pulse from Charles Gross
Alterity Therapeutics Limited (NASDAQ:ATHE) has released its Q1 FY24 report, revealing a cash balance of A$16.7M as of September 30, 2023. The company also received a A$4.74M cash refund under the Australian R&DTI Scheme and was granted a new patent by the European Patent Office. The ATH434-201 Phase 2 study is proceeding as planned.
October 30, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alterity Therapeutics has a healthy cash balance and has received additional funds from the Australian R&DTI Scheme. The continuation of the ATH434-201 Phase 2 study and the new patent grant could potentially boost investor confidence.
The company's healthy cash balance and additional funds from the Australian R&DTI Scheme indicate strong financial health. The continuation of the ATH434-201 Phase 2 study and the new patent grant are positive developments that could potentially attract more investors, thus driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100